Founded
2020
CEO
Richard Francis
Founders
Professor Moin Saleem Professor Mauro Giacca
% Shareholding
84%
Stage
Pre-clinical
Raised in a Series A in November 2020
£45m

Unless stated all figures at 31 March 2021

Purespring seeks to advance gene therapies for the treatment of chronic renal diseases that are currently poorly addressed with existing treatments.

Purespring is one of the first AAV gene therapy companies focused on the kidney globally and will seek to treat a number of debilitating chronic diseases that are currently poorly addressed with existing therapies. It has been founded around the seminal work of Professor Moin Saleem, Head of Bristol Renal where he heads a world leading group researching glomerular diseases.

Purespring has also established an in-vivo functional screening platform, FunSel, to initially screen for protective factors that could have applications across several kidney diseases. FunSel has been developed by Professor Mauro Giacca, a leader in gene therapy of cardiovascular disorders, and provides Purespring with a target discovery platform uniquely suited to systematically move gene therapy beyond monogenic disorders.

Investment opportunity

  • Opportunity to take a global lead in renal gene therapy

Unmet medical need

  • A number of chronic kidney diseases are poorly addressed by existing therapies, which are primarily based around the lowering of blood pressure and often progressing to dialysis and kidney transplantation.

Market opportunity

  • Opportunity encompasses rare monogenic diseases, as well as much more prevalent common forms of kidney disease.

Key risks

  • Highly innovative concept in emerging space

The Purespring Therapeutics pipeline

Research Pre-clinical Clinical
  • Undisclosed programme

  • Undisclosed programme

Syncona team

Chris Hollowood

Chris Hollowood

Chris is the Chief Investment Officer of Syncona Investment Management Ltd. He has been instrumental in the foundation and development of Syncona's gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Freeline, Gyroscope, SwanBio and Purespring and was also previously Chairman of Nightstar, a retinal gene the…
View Chris' biography
Position
Chair
Qualification
PhD
Alice Renard

Alice Renard

Alice is a Partner of Syncona Investment Management Ltd. She is also currently Head of Operations at Purespring Therapeutics and works closely with Anaveon. Alice serves as an Observer on the Board of Purespring and Anaveon. Prior to joining Syncona, Alice was an Investment Banking Analyst within Barclays’ Healthcare Corporate Finance and M&A team, where she worked on transactions involving ph…
View Alice's biography
Qualification
PhD
Dominic Schmidt

Dominic Schmidt

Dominic is a Partner of Syncona Investment Management Ltd. He is a a Director on the board of Anaveon, and Purespring Therapeutics. Prior to joining Syncona, Dominic worked in the life science practice of strategy consultancy L.E.K Consulting. He received his PhD from the Department of Oncology at the University of Cambridge where he was a Cancer Research UK scholar. He also holds a German Diplom…
View Dominic's biography
Position
Board member
Qualification
PhD

Purespring Therapeutics leaders and founders

Richard Francis

Richard Francis

Chief Executive Officer
Moin Saleem

Moin Saleem

Founder

Other gene therapy portfolio companies